Alping P, Neovius M, Piehl F, Frisell T, et al. Real-World Healthcare Cost Savings and Reduced Relapse Rate with Off-Label Rituximab versus Disease-Modifying Treatments Approved for Relapsing-Remitting Multiple Sclerosis: A Nationwide Cost-Effectiveness Study. Ann Neurol 2024 Mar 26. doi: 10.1002/ana.26914.
PMID: 38529711